DiaMedica Therapeutics Inc., a biopharmaceutical company operating in the clinical stage, is making significant strides in the development of treatments for neurological and kidney diseases. Its groundbreaking drug DM199, a recombinant human tissue kallikrein-1 protein, has garnered attention for its potential to treat moderate to severe chronic kidney disease caused by either Type I or Type II diabetes. The company is presently conducting Phase 2 REDUX trials on DM199, along with Phase 2/3 REMEDY2 trials for the treatment of acute ischemic stroke patients. In addition to its flagship drug, DiaMedica is also working on DM300, which is currently in pre-clinical development stages, holding the potential to provide treatment options for inflammatory diseases. Formerly known as DiaMedica Inc., the company changed its name to DiaMedica Therapeutics Inc. in December 2016. It has been incorporated since 2000 and is based in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc.'s ticker is DMAC
The company's shares trade on the NASDAQ stock exchange
They are based in Minneapolis, Minnesota
There are 1-10 employees working at DiaMedica Therapeutics Inc.
It is https://www.diamedica.com/
DiaMedica Therapeutics Inc. is in the Healthcare sector
DiaMedica Therapeutics Inc. is in the Biotechnology industry
The following five companies are DiaMedica Therapeutics Inc.'s industry peers: